• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Magenta Medical gets funding from U.S.-based VC firm

Magenta Medical gets funding from U.S.-based VC firm

July 29, 2019 By Nancy Crotti

Magenta MedicalMiniature heart pump developer Magenta Medical said today that New Enterprise Associates (NEA) has led a financing round for an undisclosed sum.

The NEA group includes existing investors such as Pitango Venture Capital and  JVC Investment Partners as well as a group of private investors led by Dr. Jacques Seguin, co-founder of ReCor Medical and founder of CoreValve. The financing will be used to advance the development of the Magenta Medical’s two products and support the company as it seeks its first FDA approval.

Israel-based Magenta Medical said its technology aims to improve the outcomes of patients admitted to the hospital with acute heart failure, whether they suffer from cardiogenic shock or from volume overload and systemic congestion.

“Acute heart failure constitutes a heterogeneous family of clinical syndromes and presents an increasing treatment challenge to caregivers and clinical teams,” said Magenta Medical CEO Dr. David Israeli in a news release. “We believe that there has never been a more critical time to develop technologies that bring real and sustained benefits to patients suffering from heart failure. We have great aspirations for our technology and know that the depth of knowledge and resources around the table, led by NEA and Pitango, puts us on a path to achieve great success in the coming years.”

To address the kidneys’ role in correcting the salt and fluid imbalance that is the hallmark of acutely decompensated heart failure, Magenta Medical has developed a transcatheter renal venous decongestion system. This device is designed to selectively reduce renal venous pressure in order to mechanically unload the kidneys, improve renal perfusion and function, and promote fluid and sodium removal. The device has been successfully tested in a human feasibility study, according to the company, which said it is working on a next-generation device.

Magenta Medical’s second product is a percutaneous left ventricular assist device (pLVAD), a miniaturized catheter-mounted arterial pump designed to move blood from the left ventricle into the aorta, unloading the failing left ventricle for hours to days and serving as a bridge-to-recovery for patients undergoing high-risk coronary interventions and admitted patients with cardiogenic shock.

“We are extremely pleased to have Magenta Medical as our first-ever medical technology investment in Israel, as it represents to us the pivotal role Israeli companies play in global life sciences innovation,” said Dr. Josh Makower, general partner and head of medtech investing at NEA.

NEA principal Dr. Tak Cheung has joined the company’s Board of Directors in conjunction with the investment.

Magenta Medical was founded by two serial entrepreneurs, Professor Ehud Schwammenthal and Yosi Tuval, who previously founded Ventor Technologies, a medical device company that was acquired by Medtronic for $325 million in 2009.

 

Filed Under: Blog, Business/Financial News, Featured, Funding Roundup, News Well, Research & Development, Structural Heart Tagged With: magentamedical, New Enterprise Associates

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy